Multipeptide Vaccine(University Hospital Tuebingen)(Multipeptide Vaccine(University Hospital Tuebingen)) - 在研适应症：成人急性髓性白血病，多形性胶质母细胞瘤，慢性淋巴细胞白血病_专利_临床

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名

Multi-peptide Vaccination Adjuvanted With the TLR1/2 Ligand XS15

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [2]

在研适应症

成人急性髓性白血病多形性胶质母细胞瘤慢性淋巴细胞白血病

非在研适应症-

原研机构

University Hospital Tübingen

在研机构

University Hospital Tübingen

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Multipeptide Vaccine(University Hospital Tuebingen) 相关的临床试验

NCT06252584

/ Not yet recruiting临床1期IIT

Multi-peptide Vaccination Adjuvanted With the TLR1/2 Ligand XS15 in Acute Myeloid Leukemia (AML) Patients Who Have Achieved Complete Remission With First Line Therapy

The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.

开始日期2024-05-02

申办/合作机构

University Hospital Tübingen

NCT04842513

/ Completed临床1期IIT

Multi Peptide Vaccination with Pam3Cys-GDPKHPKSF (XS15) As an Immunomodulator in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed HLA-A2-positive MGMT-methylated Glioblastoma

Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG

开始日期2021-05-03

申办/合作机构

University Hospital Tübingen

NCT04688385

/ Completed临床1期IIT

IVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing Ibrutinib-based Regimes

The aim of this study is to evaluate the efficiency along with safety and toxicity of a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes.

开始日期2020-12-23

申办/合作机构

University Hospital Tübingen

100 项与 Multipeptide Vaccine(University Hospital Tuebingen) 相关的临床结果

登录后查看更多信息

100 项与 Multipeptide Vaccine(University Hospital Tuebingen) 相关的转化医学

登录后查看更多信息

100 项与 Multipeptide Vaccine(University Hospital Tuebingen) 相关的专利（医药）

登录后查看更多信息

100 项与 Multipeptide Vaccine(University Hospital Tuebingen) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人急性髓性白血病	临床1期	-	University Hospital Tübingen	2024-05-02
多形性胶质母细胞瘤	临床1期	德国	University Hospital Tübingen	2021-05-03
慢性淋巴细胞白血病	临床1期	德国	University Hospital Tübingen	2020-12-23